Silo Pharma amends U. Maryland license, sets new development milestones through 2033

Silo Pharma, Inc.

Third Amendment to Master License Agreement replaces entire diligence milestone schedule (Schedule C).
Key new milestones: complete in vitro peptide binding study by March 30, 2024; preclinical safety/efficacy by Sept 30, 2024.
GMP production and animal testing deadline: Feb 12, 2026; IND filing by Feb 12, 2027; Phase 1 first dosing by Feb 12, 2028.
Phase 2 first dosing by Feb 12, 2029; NDA filing by Feb 12, 2032; first commercial sale by Feb 12, 2033.
Royalty and other payment obligations under original MLA remain unchanged.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Silo Pharma, Inc. amended Third Amendment to Master License Agreement with University of Maryland, Baltimore valued at amended and restated schedule of diligence milestones (effective 2023-11-10).

Action: amendment
Agreement: license
Counterparty: University of Maryland, Baltimore
Value: amended and restated schedule of diligence milestones
Effective: 2023-11-10

Exact text from the filing

On November 10, 2023, our wholly-owned subsidiary Silo Pharma, Inc., a Florida corporation entered into a Third Amendment to Master License Agreement (the “Third Amendment”) with the University of Maryland, Baltimore, pursuant to which the parties agreed to an amended and restated schedule of diligence milestones for the Master License Agreement.

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Silo Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-086959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.